Form 8-K Medtronic plc For: Feb 21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 8-K
_____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 21, 2017
_____________________________
Medtronic Public Limited Company
(Exact name of Registrant as Specified in its Charter)
_____________________________
Ireland | 1-36820 | 98-1183488 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
20 On Hatch, Lower Hatch Street Dublin 2, Ireland |
(Address of principal executive offices) |
(Registrant’s telephone number, including area code): +353 1 438-1700
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. | Results of Operations and Financial Condition |
On February 21, 2017, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2017 financial results and posted a related earnings presentation to the Investors section of its website. A copy of the press release and related earnings presentation are furnished as Exhibits 99.1 and 99.2 to this report.
Item 9.01. | Exhibits. |
(d) List of Exhibits
Exhibit Number | Description | |
99.1 | Press release of Medtronic plc, dated February 21, 2017 | |
99.2 | Earnings presentation, dated February 21, 2017 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDTRONIC PUBLIC LIMITED COMPANY | ||||||
By | /s/ Karen L. Parkhill | |||||
Date: February 21, 2017 | Karen L. Parkhill | |||||
Executive Vice President and Chief Financial Officer | ||||||
EXHIBIT INDEX
Exhibit Number | Description | |
99.1 | Press release of Medtronic plc, dated February 21, 2017 | |
99.2 | Earnings presentation, dated February 21, 2017 | |
Exhibit 99.1
 | ||
NEWS RELEASE | ||
Contacts: | ||||
Fernando Vivanco | Ryan Weispfenning | |||
Public Relations | Investor Relations | |||
+1-763-505-3780 | +1-763-505-4626 | |||
FOR IMMEDIATE RELEASE
MEDTRONIC REPORTS THIRD QUARTER FINANCIAL RESULTS
▪ | Revenue of $7.3 Billion Grew 5% as Reported; 6% at Constant Currency |
▪ | GAAP Diluted EPS of $0.59; Non-GAAP Diluted EPS of $1.12 |
▪ | GAAP Diluted EPS Declined 23%; Non-GAAP EPS Grew 10% at Constant Currency |
▪ | GAAP Operating Margin Declined 380 bps; Non-GAAP Operating Margin Improved 130 bps at Constant Currency |
▪ | GAAP Cash Flow from Operations of $2.1 Billion; Free Cash Flow of $1.8 Billion |
DUBLIN - February 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2017, which ended January 27, 2017.
The company reported third quarter worldwide revenue of $7.283 billion, an increase of 5 percent, or 6 percent on a constant currency basis. Foreign currency exchange had a negative $40 million impact on revenue. Third quarter GAAP net income and diluted earnings per share (EPS) were $821 million and $0.59, decreases of 25 percent and 23 percent, respectively. Third quarter non-GAAP net income and diluted EPS were $1.553 billion and $1.12, representing increases of 3 percent and 6 percent, respectively. After adjusting for the negative 5 cent impact from foreign currency exchange, non-GAAP diluted EPS increased 10 percent.
“In Q3, we achieved solid results across all of our business groups and geographies,” said Omar Ishrak, Medtronic chairman and chief executive officer. “At the same time, we produced meaningful operating profit growth based largely on our synergy programs from the Covidien integration, as well as our focus on operating excellence initiatives.”
The third quarter GAAP operating margin was 15.7 percent, a 380 basis point decline. The third quarter non-GAAP operating margin was 28.2 percent, a 40 basis point improvement. After adjusting for the 90 basis point negative impact from foreign currency exchange, the third quarter non-GAAP operating margin was 29.1 percent, representing a 130 basis point improvement.
U.S. revenue of $4.106 billion represented 56 percent of company revenue and increased 4 percent. Non-U.S. developed market revenue of $2.193 billion represented 30 percent of company revenue and increased 6 percent, or 7 percent on a constant currency basis. Emerging market revenue of $984 million represented 14 percent of company revenue and increased 9 percent, or 11 percent on a constant currency basis.
1
Cardiac and Vascular Group
The Cardiac and Vascular Group (CVG) includes the Cardiac Rhythm & Heart Failure (CRHF), Coronary & Structural Heart (CSH), and Aortic & Peripheral Vascular (APV) divisions. CVG worldwide revenue of $2.548 billion increased 5 percent, or 6 percent on a constant currency basis, driven by high-single digit constant currency growth in CRHF and APV, and low-single digit constant currency growth in CSH.
▪ | CRHF revenue of $1.371 billion increased 7 percent, or 8 percent on a constant currency basis, with mid-single digit constant currency growth in Arrhythmia Management, high-teens constant currency growth in Heart Failure, and low-double digit constant currency growth in Services & Solutions. Arrhythmia Management growth was driven in part by the continued adoption of the Arctic Front Advance® cryoballoons and Reveal LINQ® insertable cardiac monitoring systems. Heart Failure growth was driven in part by the company’s first quarter acquisition of HeartWare International, Inc. |
▪ | CSH revenue of $751 million increased 2 percent, or 3 percent on a constant currency basis, with low-double digit constant currency growth in Structural Heart, partially offset by mid-single digit constant currency declines in Coronary. Structural Heart growth was driven in part by the recent U.S. launch of the CoreValve® Evolut® R 34 mm transcatheter aortic heart valve. Coronary had double-digit constant currency declines in drug-eluting stents in the U.S. and Japan. |
▪ | APV revenue of $426 million increased 6 percent on both a reported and constant currency basis, with high-single digit growth in Peripheral Vascular and mid-single digit growth in Aortic. Growth was driven by the continued adoption of the company’s Endurant® IIs stent graft, IN.PACT® Admiral® drug-coated balloon, as well as the recent launch of the HawkOne™ 6 French directional atherectomy system. |
Minimally Invasive Therapies Group
The Minimally Invasive Therapies Group (MITG) includes the Surgical Solutions and the Patient Monitoring & Recovery (PMR) divisions. MITG worldwide revenue of $2.417 billion increased 5 percent, or 6 percent on a constant currency basis, with high-single digit constant currency growth in Surgical Solutions and mid-single digit constant currency growth in PMR.
▪ | Surgical Solutions revenue of $1.343 billion increased 6 percent, or 7 percent on a constant currency basis, driven primarily by its Open to Minimally Invasive Surgery growth initiative, including innovative new products in Advanced Stapling and Advanced Energy, including endo stapling specialty reloads, the Valleylab™ FT10 energy platform, and LigaSure™ vessel sealing instruments. The division also benefitted from the second quarter acquisition of Smith & Nephew’s gynecology business. |
▪ | PMR revenue of $1.074 billion increased 5 percent on both a reported and constant currency basis. This is a result of strong growth in the Airways and Ventilation business, driven by continued adoption of the Puritan Bennett™ 980 ventilator, and in the Patient Monitoring business, driven by strength in Nellcor™ pulse oximetry. PMR also benefitted from the fiscal year 2016 fourth quarter acquisition of Bellco in the Renal Care Solutions business. |
Restorative Therapies Group
The Restorative Therapies Group (RTG) includes the Spine, Brain Therapies, Specialty Therapies, and Pain Therapies divisions. RTG worldwide revenue of $1.817 billion increased 4 percent on both a reported and constant currency basis. Group results were driven by high-single digit growth in Brain Therapies, mid-single digit growth in Specialty Therapies, and low-single digit growth in Spine, offsetting declines in Pain Therapies, all on a constant currency basis.
▪ | Spine revenue of $657 million increased 3 percent on both a reported and constant currency basis, the division’s strongest growth in over 7 years. Core Spine grew in the low-single digits on a constant currency basis, as the focus on “Speed-to-Scale” new product launches continues to drive improved results. BMP also grew in the low-single digits on a constant currency basis. |
▪ | Brain Therapies revenue of $518 million increased 7 percent, or 8 percent on a constant currency basis. Neurovascular grew in the low-double digits on a constant currency basis, driven in part by sales of the Axium™ Prime Extra Soft detachable coil and the Pipeline™ Flex embolization device. Neurosurgery grew in the high-single digits on a constant currency basis, driven by strong growth in navigation capital equipment and disposables, as well as continued solid adoption of the O-arm® O2 surgical imaging system. Brain Modulation grew in the low-single digits on a constant currency basis on the strength of the company’s MR conditional Activa® DBS portfolio. |
▪ | Specialty Therapies revenue of $370 million increased 4 percent, or 5 percent on a constant currency basis. All three businesses contributed to growth, with Advanced Energy growing in the low-double digits, Pelvic Health growing in the mid-single digits, and ENT growing in the low-single digits, all on a constant currency basis. |
▪ | Pain Therapies revenue of $272 million decreased 3 percent, or 2 percent on a constant currency basis. After adjusting for the divestiture of the division’s drug business, which occurred in the third quarter of fiscal year 2016, Pain Therapies revenue was flat on both a reported and constant currency basis. Pain Therapies had low-single digit constant currency declines in Spinal Cord Stimulation, as the business faced competitive pressures, and low-single digit constant currency declines in Drug Pumps, partially offset by high-single digit constant currency growth in the Interventional business. |
2
Diabetes Group
The Diabetes Group includes the Intensive Insulin Management (IIM), Non-Intensive Diabetes Therapies (NDT), and Diabetes Service & Solutions (DSS) divisions. Diabetes Group worldwide revenue of $501 million increased 6 percent, or 7 percent on a constant currency basis, with all three divisions contributing to growth.
▪ | IIM grew in the low double-digits on a constant currency basis, with low double-digit growth in the U.S. driven by strong interest in the MiniMed® 630G system and the Priority Access Program for the MiniMed® 670G system. In addition, the division delivered high-single digit constant currency growth in international markets as a result of continued strong sales in Europe and Asia Pacific of the MiniMed® 640G system. The division continues to be on track for a spring U.S. launch of the MiniMed® 670G system, the world’s first hybrid closed loop insulin delivery system. |
▪ | NDT grew in the high-teens on a constant currency basis, led by the sales of the iPro®2 Professional Continuous Glucose Monitor (CGM) technology with Pattern Snapshot to primary care physicians. |
▪ | DSS grew in the low-single digits on a constant currency basis, with double-digit constant currency growth in international markets as a result of strong growth in consumables and Diabeter clinic revenue, offsetting low-single digit U.S. declines. |
Outlook and Guidance
The company today reiterated its fiscal year 2017 revenue outlook, EPS guidance, and free cash flow outlook.
The company continues to expect fiscal year 2017 revenue growth to be within the mid-single digit range on a constant currency, constant weeks basis, which is consistent with the company’s long-term, mid-single digit constant currency revenue growth expectation. The company expects revenue growth for the fourth quarter of fiscal year 2017 to be in the lower half of the mid-single digit range on a constant currency basis. While the impact from foreign currency exchange is fluid, if current exchange rates remain similar for the remainder of the fiscal year, the company’s full year revenue and fourth fiscal quarter would both be negatively affected by approximately $20 million to $40 million.
The company continues to expect fiscal year 2017 diluted non-GAAP EPS growth to be in the double digits on a constant currency, constant week basis, which is consistent with the company’s long-term, double digit constant currency EPS growth expectation. Taking into account the estimated 8 to 10 cent impact from the extra week in the first quarter last fiscal year, the estimated negative impact from foreign currency exchange of approximately 20 cents, and assuming current exchange rates remain similar for the rest of the year, this growth guidance implies fiscal year 2017 non-GAAP diluted EPS in the range of $4.55 to $4.60.
For fiscal year 2017, the company continues to expect free cash flow to be in the range of $5 billion to $6 billion.
“We remain confident in our ability to deliver mid-single digit constant currency revenue growth and double-digit constant currency EPS growth, not only in our current fiscal year, but also into the future,” said Ishrak. “With our differentiated growth platforms and leadership in strong healthcare growth markets, we believe we are well positioned to create long-term, dependable value for our shareholders.”
Webcast Information
Medtronic will host a webcast today, February 21, at 8:00 a.m. EST (7:00 a.m. CST) to provide information about its businesses for the public, investors, analysts, and news media. This quarterly webcast can be accessed by clicking on the Investor Events link at investorrelations.medtronic.com and this earnings release will be archived at newsroom.medtronic.com. Medtronic will be live tweeting during the webcast on our Newsroom Twitter account, @Medtronic. Within 24 hours of the webcast, a replay of the webcast and transcript of the company’s prepared remarks will be available by clicking on the Investor Events link at investorrelations.medtronic.com.
Financial Schedules
To view the third quarter financial schedules and non-GAAP reconciliations, click here. To view the third quarter earnings presentation, click here. Both of these documents can also be accessed by visiting newsroom.medtronic.com.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
3
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements related to product and service growth drivers, market position and opportunities, the transforming healthcare environment, strategies for and sustainability of growth, benefits from collaborations and acquisitions, availability of and plans for cash, the creation of shareholder value and shareholder returns, product launches, and Medtronic’s future results of operations, which are subject to risks and uncertainties, such as competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, challenges with respect to third-party collaborations and integration of acquired businesses, effectiveness of growth and restructuring strategies, challenges relating to our worldwide operations, challenges or unforeseen risks in implementing our growth strategies, government regulation, fluctuations in foreign currency exchange rates, future revenue and earnings growth, and general economic conditions and other risks and uncertainties described in Medtronic’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). Anticipated results only reflect information available to Medtronic at this time and may differ from actual results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release. Certain information in this press release includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm, including but not limited to, certain information in the financial schedules accompanying this press release. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material.
NON-GAAP FINANCIAL MEASURES
This press release contains financial measures and guidance, including free cash flow figures (defined as operating cash flows less property, plant and equipment additions), revenue and growth rates on a constant currency basis, net income, and diluted EPS, all of which are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Unless otherwise noted, all revenue amounts given in this press release are stated in accordance with U.S. generally accepted accounting principles (GAAP). References to quarterly figures increasing or decreasing are in comparison to the third quarter of fiscal year 2016.
Medtronic management believes that in order to properly understand its short-term and long-term financial trends, including period over period comparisons of the company’s operations, investors may find it useful to exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management’s review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP, and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.
Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking revenue growth and EPS projections exclude the impact of foreign currency exchange fluctuations. Forward-looking non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as non-GAAP adjustments to earnings during the fiscal year, such as amortization of intangible assets and acquisition-related, certain tax and litigation, and restructuring charges or gains. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, we believe such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
-end-
View FY17 Third Quarter Financial Schedules & Non-GAAP Reconciliations
View FY17 Third Quarter Earnings Presentation
4
5
MEDTRONIC PLC
WORLD WIDE REVENUE
(Unaudited)
THIRD QUARTER AS REPORTED | THIRD QUARTER CONSTANT CURRENCY ADJUSTED | THIRD QUARTER YTD AS REPORTED | THIRD QUARTER YTD CONSTANT CURRENCY ADJUSTED | |||||||||||||||||||||||||||||||||||||||||
(in millions) | FY17 Q3 | FY16 Q3 | Reported Growth | Currency Impact on Revenue | FY17 Q3 | Constant Currency Growth (2) | FY17 Q3 YTD | FY16 Q3 YTD | Reported Growth (1) | Currency Impact on Revenue | FY17 Q3 YTD | Constant Currency Growth (1)(2) | ||||||||||||||||||||||||||||||||
Cardiac & Vascular Group | $ | 2,548 | $ | 2,416 | 5 | % | $ | (23 | ) | $ | 2,571 | 6 | % | $ | 7,650 | $ | 7,476 | 2 | % | $ | (18 | ) | $ | 7,668 | 3 | % | ||||||||||||||||||
Cardiac Rhythm & Heart Failure | 1,371 | 1,278 | 7 | (12 | ) | 1,383 | 8 | 4,105 | 3,973 | 3 | (3 | ) | 4,108 | 3 | ||||||||||||||||||||||||||||||
Coronary & Structural Heart | 751 | 736 | 2 | (9 | ) | 760 | 3 | 2,266 | 2,277 | — | (16 | ) | 2,282 | — | ||||||||||||||||||||||||||||||
Aortic & Peripheral Vascular (3) | 426 | 402 | 6 | (2 | ) | 428 | 6 | 1,279 | 1,226 | 4 | 1 | 1,278 | 4 | |||||||||||||||||||||||||||||||
Minimally Invasive Therapies Group | 2,417 | 2,291 | 5 | (5 | ) | 2,422 | 6 | 7,314 | 7,103 | 3 | 27 | 7,287 | 3 | |||||||||||||||||||||||||||||||
Surgical Solutions | 1,343 | 1,264 | 6 | (5 | ) | 1,348 | 7 | 4,052 | 3,907 | 4 | 7 | 4,045 | 4 | |||||||||||||||||||||||||||||||
Patient Monitoring & Recovery | 1,074 | 1,027 | 5 | — | 1,074 | 5 | 3,262 | 3,196 | 2 | 20 | 3,242 | 1 | ||||||||||||||||||||||||||||||||
Restorative Therapies Group (3) | 1,817 | 1,753 | 4 | (7 | ) | 1,824 | 4 | 5,415 | 5,319 | 2 | 3 | 5,412 | 2 | |||||||||||||||||||||||||||||||
Spine | 657 | 636 | 3 | — | 657 | 3 | 1,965 | 1,970 | — | 6 | 1,959 | (1 | ) | |||||||||||||||||||||||||||||||
Brain Therapies | 518 | 483 | 7 | (3 | ) | 521 | 8 | 1,513 | 1,420 | 7 | (1 | ) | 1,514 | 7 | ||||||||||||||||||||||||||||||
Specialty Therapies | 370 | 355 | 4 | (2 | ) | 372 | 5 | 1,095 | 1,048 | 4 | (1 | ) | 1,096 | 5 | ||||||||||||||||||||||||||||||
Pain Therapies | 272 | 279 | (3 | ) | (2 | ) | 274 | (2 | ) | 842 | 881 | (4 | ) | (1 | ) | 843 | (4 | ) | ||||||||||||||||||||||||||
Diabetes Group | 501 | 474 | 6 | (5 | ) | 506 | 7 | 1,415 | 1,368 | 3 | (9 | ) | 1,424 | 4 | ||||||||||||||||||||||||||||||
TOTAL | $ | 7,283 | $ | 6,934 | 5 | % | $ | (40 | ) | $ | 7,323 | 6 | % | $ | 21,794 | $ | 21,266 | 2 | % | $ | 3 | $ | 21,791 | 2 | % | |||||||||||||||||||
See description of non-GAAP financial measures at the end of the earnings press release.
(1) Fiscal year 2016 was a 53-week year, with the extra week included in the first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates that the extra week impact on first quarter revenue was approximately $450 million.
(2) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior year periods using average exchange rates in effect during the applicable prior year period.
(3) In fiscal year 2017, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from certain product lines in Restorative Therapies Group to Cardiac & Vascular Group's Aortic & Peripheral Vascular division. As a result, fiscal year 2016 results have been recast to adjust for this realignment.
6
MEDTRONIC PLC
U.S.(3) REVENUE
(Unaudited)
THIRD QUARTER AS REPORTED | THIRD QUARTER YTD AS REPORTED | |||||||||||||||||||||
(in millions) | FY17 Q3 | FY16 Q3 | Reported Growth | FY17 Q3 YTD | FY16 Q3 YTD | Reported Growth (1) | ||||||||||||||||
Cardiac & Vascular Group | $ | 1,320 | $ | 1,256 | 5 | % | $ | 3,970 | $ | 3,952 | — | % | ||||||||||
Cardiac Rhythm & Heart Failure | 783 | 729 | 7 | 2,346 | 2,282 | 3 | ||||||||||||||||
Coronary & Structural Heart | 289 | 291 | (1 | ) | 872 | 942 | (7 | ) | ||||||||||||||
Aortic & Peripheral Vascular (2) | 248 | 236 | 5 | 752 | 728 | 3 | ||||||||||||||||
Minimally Invasive Therapies Group | 1,234 | 1,207 | 2 | 3,735 | 3,762 | (1 | ) | |||||||||||||||
Surgical Solutions | 582 | 545 | 7 | 1,745 | 1,706 | 2 | ||||||||||||||||
Patient Monitoring & Recovery | 652 | 662 | (2 | ) | 1,990 | 2,056 | (3 | ) | ||||||||||||||
Restorative Therapies Group (2) | 1,242 | 1,209 | 3 | 3,710 | 3,644 | 2 | ||||||||||||||||
Spine | 466 | 457 | 2 | 1,387 | 1,373 | 1 | ||||||||||||||||
Brain Therapies | 296 | 274 | 8 | 867 | 810 | 7 | ||||||||||||||||
Specialty Therapies | 282 | 271 | 4 | 841 | 802 | 5 | ||||||||||||||||
Pain Therapies | 198 | 207 | (4 | ) | 615 | 659 | (7 | ) | ||||||||||||||
Diabetes Group | 310 | 293 | 6 | 845 | 847 | — | ||||||||||||||||
TOTAL | $ | 4,106 | $ | 3,965 | 4 | % | $ | 12,260 | $ | 12,205 | — | % | ||||||||||
(1) Fiscal year 2016 was a 53-week year, with the extra week included in the first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates that the extra week impact on first quarter revenue was approximately $450 million.
(2) In fiscal year 2017, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from certain product lines in Restorative Therapies Group to Cardiac & Vascular Group's Aortic & Peripheral Vascular division. As a result, fiscal year 2016 results have been recast to adjust for this realignment.
(3) U.S. includes the United States and U.S. territories.
7
MEDTRONIC PLC
WORLD WIDE REVENUE: GEOGRAPHIC(4)
(Unaudited)
THIRD QUARTER AS REPORTED | THIRD QUARTER CONSTANT CURRENCY ADJUSTED | THIRD QUARTER YTD AS REPORTED | THIRD QUARTER YTD CONSTANT CURRENCY ADJUSTED | |||||||||||||||||||||||||||||||||||||||||
(in millions) | FY17 Q3 | FY16 Q3 | Reported Growth | Currency Impact on Revenue | FY17 Q3 | Constant Currency Growth (2) | FY17 Q3 YTD | FY16 Q3 YTD | Reported Growth (1) | Currency Impact on Revenue | FY17 Q3 YTD | Constant Currency Growth (1)(2) | ||||||||||||||||||||||||||||||||
U.S. | $ | 1,320 | $ | 1,256 | 5 | % | $ | — | $ | 1,320 | 5 | % | $ | 3,970 | $ | 3,952 | — | % | $ | — | $ | 3,970 | — | % | ||||||||||||||||||||
Non-U.S. Developed | 815 | 775 | 5 | (13 | ) | 828 | 7 | 2,467 | 2,378 | 4 | 18 | 2,449 | 3 | |||||||||||||||||||||||||||||||
Emerging Markets | 413 | 385 | 7 | (10 | ) | 423 | 10 | 1,213 | 1,146 | 6 | (36 | ) | 1,249 | 9 | ||||||||||||||||||||||||||||||
Cardiac & Vascular Group (3) | 2,548 | 2,416 | 5 | (23 | ) | 2,571 | 6 | 7,650 | 7,476 | 2 | (18 | ) | 7,668 | 3 | ||||||||||||||||||||||||||||||
U.S. | 1,234 | 1,207 | 2 | — | 1,234 | 2 | 3,735 | 3,762 | (1 | ) | — | 3,735 | (1 | ) | ||||||||||||||||||||||||||||||
Non-U.S. Developed | 842 | 780 | 8 | 1 | 841 | 8 | 2,558 | 2,398 | 7 | 58 | 2,500 | 4 | ||||||||||||||||||||||||||||||||
Emerging Markets | 341 | 304 | 12 | (6 | ) | 347 | 14 | 1,021 | 943 | 8 | (31 | ) | 1,052 | 12 | ||||||||||||||||||||||||||||||
Minimally Invasive Therapies Group | 2,417 | 2,291 | 5 | (5 | ) | 2,422 | 6 | 7,314 | 7,103 | 3 | 27 | 7,287 | 3 | |||||||||||||||||||||||||||||||
U.S. | 1,242 | 1,209 | 3 | — | 1,242 | 3 | 3,710 | 3,644 | 2 | — | 3,710 | 2 | ||||||||||||||||||||||||||||||||
Non-U.S. Developed | 384 | 367 | 5 | (1 | ) | 385 | 5 | 1,151 | 1,121 | 3 | 21 | 1,130 | 1 | |||||||||||||||||||||||||||||||
Emerging Markets | 191 | 177 | 8 | (6 | ) | 197 | 11 | 554 | 554 | — | (18 | ) | 572 | 3 | ||||||||||||||||||||||||||||||
Restorative Therapies Group (3) | 1,817 | 1,753 | 4 | (7 | ) | 1,824 | 4 | 5,415 | 5,319 | 2 | 3 | 5,412 | 2 | |||||||||||||||||||||||||||||||
U.S. | 310 | 293 | 6 | — | 310 | 6 | 845 | 847 | — | — | 845 | — | ||||||||||||||||||||||||||||||||
Non-U.S. Developed | 152 | 144 | 6 | (5 | ) | 157 | 9 | 457 | 418 | 9 | (7 | ) | 464 | 11 | ||||||||||||||||||||||||||||||
Emerging Markets | 39 | 37 | 5 | — | 39 | 5 | 113 | 103 | 10 | (2 | ) | 115 | 12 | |||||||||||||||||||||||||||||||
Diabetes Group | 501 | 474 | 6 | (5 | ) | 506 | 7 | 1,415 | 1,368 | 3 | (9 | ) | 1,424 | 4 | ||||||||||||||||||||||||||||||
U.S. | 4,106 | 3,965 | 4 | — | 4,106 | 4 | 12,260 | 12,205 | — | — | 12,260 | — | ||||||||||||||||||||||||||||||||
Non-U.S. Developed | 2,193 | 2,066 | 6 | (18 | ) | 2,211 | 7 | 6,633 | 6,315 | 5 | 90 | 6,543 | 4 | |||||||||||||||||||||||||||||||
Emerging Markets | 984 | 903 | 9 | (22 | ) | 1,006 | 11 | 2,901 | 2,746 | 6 | (87 | ) | 2,988 | 9 | ||||||||||||||||||||||||||||||
TOTAL | $ | 7,283 | $ | 6,934 | 5 | % | $ | (40 | ) | $ | 7,323 | 6 | % | $ | 21,794 | $ | 21,266 | 2 | % | $ | 3 | $ | 21,791 | 2 | % | |||||||||||||||||||
See description of non-GAAP financial measures at the end of the earnings press release.
(1) Fiscal year 2016 was a 53-week year, with the extra week included in the first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates that the extra week impact on first quarter revenue was approximately $450 million.
(2) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior year periods using average exchange rates in effect during the applicable prior year period.
(3) In fiscal year 2017, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from certain product lines in Restorative Therapies Group to Cardiac & Vascular Group's Aortic & Peripheral Vascular division. As a result, fiscal year 2016 results have been recast to adjust for this realignment.
(4) U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.
8
MEDTRONIC PLC
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three months ended | Nine months ended | |||||||||||||||
(in millions, except per share data) | January 27, 2017 | January 29, 2016 | January 27, 2017 | January 29, 2016 | ||||||||||||
Net sales | $ | 7,283 | $ | 6,934 | $ | 21,794 | $ | 21,266 | ||||||||
Costs and expenses: | ||||||||||||||||
Cost of products sold | 2,268 | 2,141 | 6,855 | 6,779 | ||||||||||||
Research and development expense | 530 | 546 | 1,640 | 1,649 | ||||||||||||
Selling, general, and administrative expense | 2,388 | 2,317 | 7,232 | 7,109 | ||||||||||||
Special charge | 100 | — | 100 | — | ||||||||||||
Restructuring charges, net | 21 | 19 | 162 | 159 | ||||||||||||
Certain litigation charges | 218 | — | 300 | 26 | ||||||||||||
Acquisition-related items | 68 | 63 | 148 | 183 | ||||||||||||
Amortization of intangible assets | 497 | 484 | 1,484 | 1,448 | ||||||||||||
Other expense, net | 46 | 9 | 174 | 127 | ||||||||||||
Operating profit | 1,147 | 1,355 | 3,699 | 3,786 | ||||||||||||
Interest income | (88 | ) | (99 | ) | (272 | ) | (321 | ) | ||||||||
Interest expense | 268 | 275 | 804 | 905 | ||||||||||||
Interest expense, net | 180 | 176 | 532 | 584 | ||||||||||||
Income from operations before income taxes | 967 | 1,179 | 3,167 | 3,202 | ||||||||||||
Provision for income taxes | 147 | 84 | 307 | 767 | ||||||||||||
Net income | 820 | 1,095 | 2,860 | 2,435 | ||||||||||||
Net loss attributable to noncontrolling interests | (1 | ) | — | (5 | ) | — | ||||||||||
Net income attributable to Medtronic | $ | 821 | $ | 1,095 | $ | 2,865 | $ | 2,435 | ||||||||
Basic earnings per share | $ | 0.60 | $ | 0.78 | $ | 2.07 | $ | 1.72 | ||||||||
Diluted earnings per share | $ | 0.59 | $ | 0.77 | $ | 2.05 | $ | 1.70 | ||||||||
Basic weighted average shares outstanding | 1,372.2 | 1,406.6 | 1,381.9 | 1,412.5 | ||||||||||||
Diluted weighted average shares outstanding | 1,383.1 | 1,422.2 | 1,394.7 | 1,429.2 | ||||||||||||
Cash dividends declared per ordinary share | $ | 0.43 | $ | 0.38 | $ | 1.29 | $ | 1.14 | ||||||||
9
MEDTRONIC PLC
NET INCOME AND DILUTED EPS GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)
Three months ended January 27, 2017 | ||||||||||||||||||||||||||||||||
(in millions, except per share data) | Net Sales | Cost of Products Sold | Gross Margin Percent | Operating Profit | Operating Profit Percent | Income from Operations Before Income Taxes | Net Income attributable to Medtronic | Diluted EPS (1) | Effective Tax Rate | |||||||||||||||||||||||
GAAP | $ | 7,283 | $ | 2,268 | 68.9 | % | $ | 1,147 | 15.7 | % | $ | 967 | $ | 821 | $ | 0.59 | 15.2 | % | ||||||||||||||
Non-GAAP Adjustments: (2) | ||||||||||||||||||||||||||||||||
Special charge (a) | — | — | 100 | 100 | 63 | 0.05 | 37.0 | |||||||||||||||||||||||||
Restructuring charges, net | — | — | 21 | 21 | 19 | 0.01 | 9.5 | |||||||||||||||||||||||||
Certain litigation charges | — | — | 218 | 218 | 138 | 0.10 | 36.7 | |||||||||||||||||||||||||
Acquisition-related items | — | — | 68 | 68 | 52 | 0.04 | 23.5 | |||||||||||||||||||||||||
Amortization of intangible assets | — | — | 497 | 497 | 374 | 0.27 | 24.7 | |||||||||||||||||||||||||
Certain tax adjustment (b) | — | — | — | — | 86 | 0.06 | — | |||||||||||||||||||||||||
Non-GAAP | $ | 7,283 | $ | 2,268 | 68.9 | % | $ | 2,051 | 28.2 | % | $ | 1,871 | $ | 1,553 | $ | 1.12 | 17.0 | % | ||||||||||||||
Foreign currency impact | 40 | (10 | ) | 0.3 | 78 | 0.9 | 0.05 | |||||||||||||||||||||||||
Constant Currency Adjusted | $ | 7,323 | $ | 2,258 | 69.2 | % | $ | 2,129 | 29.1 | % | $ | 1.17 | ||||||||||||||||||||
Three months ended January 29, 2016 | ||||||||||||||||||||||||||||||||
(in millions, except per share data) | Net Sales | Cost of Products Sold | Gross Margin Percent | Operating Profit | Operating Profit Percent | Income from Operations Before Income Taxes | Net Income attributable to Medtronic | Diluted EPS (1) | Effective Tax Rate | |||||||||||||||||||||||
GAAP | $ | 6,934 | $ | 2,141 | 69.1 | % | $ | 1,355 | 19.5 | % | $ | 1,179 | $ | 1,095 | $ | 0.77 | 7.1 | % | ||||||||||||||
Non-GAAP Adjustments: (2) | ||||||||||||||||||||||||||||||||
Restructuring charges, net | — | (9 | ) | 28 | 28 | 16 | 0.01 | 42.9 | ||||||||||||||||||||||||
Acquisition-related items | — | — | 63 | 63 | 43 | 0.03 | 31.7 | |||||||||||||||||||||||||
Amortization of intangible assets | — | — | 484 | 484 | 374 | 0.26 | 22.7 | |||||||||||||||||||||||||
Certain tax adjustment (c) | — | — | — | — | (25 | ) | (0.02 | ) | — | |||||||||||||||||||||||
Non-GAAP | $ | 6,934 | $ | 2,132 | 69.3 | % | $ | 1,930 | 27.8 | % | $ | 1,754 | $ | 1,503 | $ | 1.06 | 14.3 | % | ||||||||||||||
Year over year percent change: | Net Income | Diluted EPS | ||||||||||||||||||||||||||||||
GAAP | (25)% | (23)% | ||||||||||||||||||||||||||||||
Non-GAAP | 3% | 6% | ||||||||||||||||||||||||||||||
Constant Currency Adjusted Non-GAAP | 10% | |||||||||||||||||||||||||||||||
See description of non-GAAP financial measures at the end of the earnings press release.
(1) | The data in this schedule has been intentionally rounded to the nearest $0.01 and, therefore, may not sum. |
(2) | Non-GAAP adjustments relate to charges or benefits that management believes may or may not recur with similar materiality or impact on results in future periods. |
(a) | The charge represents a contribution to the Medtronic Foundation. |
(b) | The charge relates to the IRS's disallowance of the utilization of certain net operating losses and the recording of a valuation allowance against the net operating loss deferred tax asset. |
(c) | The benefit relates to the establishment of a deferred tax asset on the tax basis in excess of book basis of a wholly owned U.S. subsidiary of which the Company disposed. |
10
MEDTRONIC PLC
NET INCOME AND DILUTED EPS GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)
Nine months ended January 27, 2017 | ||||||||||||||||||||||||||||||||
(in millions, except per share data) | Net Sales | Cost of Products Sold | Gross Margin Percent | Operating Profit | Operating Profit Percent | Income from Operations Before Taxes | Net Income attributable to Medtronic | Diluted EPS (1) | Effective Tax Rate | |||||||||||||||||||||||
GAAP | $ | 21,794 | $ | 6,855 | 68.5 | % | $ | 3,699 | 17.0 | % | $ | 3,167 | $ | 2,865 | $ | 2.05 | 9.7 | % | ||||||||||||||
Non-GAAP Adjustments: (2) | ||||||||||||||||||||||||||||||||
Impact of inventory step-up (a) | — | (38 | ) | 38 | 38 | 24 | 0.02 | 36.8 | ||||||||||||||||||||||||
Special charge (b) | — | — | 100 | 100 | 63 | 0.05 | 37.0 | |||||||||||||||||||||||||
Restructuring charges, net | — | (10 | ) | 172 | 172 | 132 | 0.09 | 23.3 | ||||||||||||||||||||||||
Certain litigation charges | — | — | 300 | 300 | 190 | 0.14 | 36.7 | |||||||||||||||||||||||||
Acquisition-related items | — | — | 148 | 148 | 93 | 0.07 | 37.2 | |||||||||||||||||||||||||
Amortization of intangible assets | — | — | 1,484 | 1,484 | 1,135 | 0.81 | 23.5 | |||||||||||||||||||||||||
Certain tax adjustments (c) | — | — | — | — | 55 | 0.04 | — | |||||||||||||||||||||||||
Non-GAAP | $ | 21,794 | $ | 6,807 | 68.8 | % | $ | 5,941 | 27.3 | % | $ | 5,409 | $ | 4,557 | $ | 3.27 | 15.8 | % | ||||||||||||||
Foreign currency impact | (3 | ) | (87 | ) | 0.4 | 256 | 1.1 | 0.15 | ||||||||||||||||||||||||
Constant Currency Adjusted | $ | 21,791 | $ | 6,720 | 69.2 | % | $ | 6,197 | 28.4 | % | $ | 3.42 | ||||||||||||||||||||
Nine months ended January 29, 2016 | ||||||||||||||||||||||||||||||||
(in millions, except per share data) | Net Sales | Cost of Products Sold | Gross Margin Percent | Operating Profit | Operating Profit Percent | Income from Operations Before Taxes | Net Income attributable to Medtronic | Diluted EPS (1) | Effective Tax Rate | |||||||||||||||||||||||
GAAP | $ | 21,266 | $ | 6,779 | 68.1 | % | $ | 3,786 | 17.8 | % | $ | 3,202 | $ | 2,435 | $ | 1.70 | 24.0 | % | ||||||||||||||
Non-GAAP Adjustments: (2) | ||||||||||||||||||||||||||||||||
Impact of inventory step-up (d) | — | (226 | ) | 226 | 226 | 165 | 0.12 | 27.0 | ||||||||||||||||||||||||
Restructuring charges, net | — | (9 | ) | 167 | 167 | 124 | 0.09 | 25.7 | ||||||||||||||||||||||||
Certain litigation charges | — | — | 26 | 26 | 17 | 0.01 | 34.6 | |||||||||||||||||||||||||
Acquisition-related items | — | — | 183 | 183 | 126 | 0.09 | 31.1 | |||||||||||||||||||||||||
Loss on previously held forward starting interest rate swaps (e) | — | — | — | 45 | 29 | 0.02 | 35.6 | |||||||||||||||||||||||||
Amortization of intangible assets | — | — | 1,448 | 1,448 | 1,119 | 0.78 | 22.7 | |||||||||||||||||||||||||
Certain tax adjustments (f) | — | — | — | — | 417 | 0.29 | — | |||||||||||||||||||||||||
Non-GAAP | $ | 21,266 | $ | 6,544 | 69.2 | % | $ | 5,836 | 27.4 | % | $ | 5,297 | $ | 4,432 | $ | 3.10 | 16.3 | % | ||||||||||||||
Year over year percent change: | Net Income | Diluted EPS | ||||||||||||||||||||||||||||||
GAAP | 18% | 21% | ||||||||||||||||||||||||||||||
Non-GAAP | 3% | 5% | ||||||||||||||||||||||||||||||
Constant Currency Adjusted Non-GAAP | 10% | |||||||||||||||||||||||||||||||
See description of non-GAAP financial measures contained in this release.
(1) | The data in this schedule has been intentionally rounded to the nearest $0.01 and, therefore, may not sum. |
(2) | Non-GAAP adjustments relate to charges or benefits that management believes may or may not recur with similar materiality or impact on results in future periods. |
(a) | Represents amortization of step-up in fair value of inventory acquired in connection with the HeartWare acquisition. |
(b) | The charge represents a contribution to the Medtronic Foundation. |
(c) | The net charge relates to the IRS's disallowance of the utilization of certain net operating losses and the recording of a valuation allowance against the net operating loss deferred tax asset, and other certain tax charges recorded in |
11
connection with the redemption of an intercompany minority interest, partially offset by a benefit related to the resolution of various tax positions from prior years.
(d) | Represents amortization of step-up in fair value of inventory acquired in connection with the Covidien acquisition. |
(e) | Relates to losses incurred from the unwinding of forward starting interest rate swaps, which were previously entered into in advance of a planned debt issuance that is no longer expected post the internal reorganization described in footnote (f). The losses were recorded in interest expense, net in our consolidated statements of income. |
(f) | Primarily relates to U.S. income tax expense resulting from the Company's completion of an internal reorganization of the ownership of certain legacy Covidien businesses that reduced the cash and investments held by Medtronic’s U.S.-controlled non-U.S. subsidiaries. Also includes a benefit related to the establishment of a deferred tax asset on the tax basis in excess of book basis of a wholly owned U.S. subsidiary of which the Company disposed. |
12
MEDTRONIC PLC
RECONCILIATION OF OPERATING CASH FLOW TO FREE CASH FLOW
(Unaudited)
Nine months ended | Six months ended | Three months ended | |||||||||
(in millions) | January 27, 2017 | October 28, 2016 | January 27, 2017 | ||||||||
Net cash provided by operating activities | $ | 5,107 | $ | 3,022 | $ | 2,085 | |||||
Additions to property, plant, and equipment | (924 | ) | (598 | ) | (326 | ) | |||||
Free Cash Flow (1) | $ | 4,183 | $ | 2,424 | $ | 1,759 | |||||
See description of non-GAAP financial measures at the end of the earnings press release.
(1) | Free cash flow represents operating cash flows less property, plant, and equipment additions. |
13
MEDTRONIC PLC
RECONCILIATION OF ESTIMATED FULL FISCAL YEAR OPERATING CASH FLOW TO FREE CASH FLOW
(Unaudited)
Full Fiscal Year 2017 Estimate | ||||||||
(in billions) | Low | High | ||||||
Net cash provided by operating activities (1) | $ | 6.2 | $ | 7.1 | ||||
Additions to property, plant, and equipment | (1.2 | ) | (1.1 | ) | ||||
Free Cash Flow (2) | $ | 5.0 | $ | 6.0 | ||||
See description of non-GAAP financial measures at the end of the earnings press release.
(1) | Estimated full fiscal year net cash provided by operating activities includes assumptions related to the timing and amount of cash flows resulting from charges or gains that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). The estimated full year range is broad to capture the unpredictability inherent in the timing and amount of cash flows related to Non-GAAP Adjustments. The estimate includes projected cash flows related to Non-GAAP Adjustments which have been recognized in the Company's statements of income. If the Company were to incur charges or gains related to Non-GAAP Adjustments which have not yet been recognized in the statements of income, the estimated full fiscal year net cash provided by operating activities may be significantly effected. |
(2) | Free cash flow represents operating cash flows less property, plant, and equipment additions. |
14
MEDTRONIC PLC
THIRD QUARTER SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE (SG&A), RESEARCH AND DEVELOPMENT EXPENSE (R&D), AND OTHER (INCOME) EXPENSE, NET ON AN ADJUSTED BASIS
(Unaudited)
Three months ended January 27, 2017 | ||||||||||||||||||||||||
(in millions) | Net Sales | SG&A Expense | SG&A Expense as a Percentage of Net Sales | R&D Expense | R&D Expense as a Percentage of Net Sales | Other (Income) Expense, net | Other (Income) Expense, net as a Percentage of Net Sales | |||||||||||||||||
As reported | $ | 7,283 | $ | 2,388 | 32.8 | % | $ | 530 | 7.3 | % | $ | 46 | 0.6 | % | ||||||||||
Foreign currency impact | 40 | 9 | 1 | (38 | ) | |||||||||||||||||||
Adjusted | $ | 7,323 | $ | 2,397 | 32.7 | % | $ | 531 | 7.3 | % | $ | 8 | 0.1 | % | ||||||||||
See description of non-GAAP financial measures at the end of the earnings press release.
15
MEDTRONIC PLC
REVENUE AND OPERATING PROFIT PERCENT GAAP TO NON-GAAP RECONCILIATIONS
(Unaudited)
Three months ended January 27, 2017 | |||||
Revenue | Operating Profit Percent | ||||
Reported | 5.0 | % | 15.7 | % | |
Non-GAAP adjustments (1) | — | 12.5 | |||
Foreign currency impact (2) | 0.6 | 0.9 | |||
Non-GAAP constant currency adjusted | 5.6 | 29.1 | |||
Impact from acquisitions and divestitures | (1.5 | ) | 0.4 | ||
Adjusted | 4.1 | % | 29.5 | % | |
See description of non-GAAP financial measures at the end of the earnings press release.
(1) | Non-GAAP adjustments relate to charges or gains that management believes may or may not recur with similar materiality or impact on results in future periods. |
(2) | Constant currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior year periods using average exchange rates in effect during the applicable prior year period. |
16
MEDTRONIC PLC
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in millions) | January 27, 2017 | April 29, 2016 | ||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 2,768 | $ | 2,876 | ||||
Investments | 8,690 | 9,758 | ||||||
Accounts receivable, less allowances of $168 and $161, respectively | 5,453 | 5,562 | ||||||
Inventories | 3,720 | 3,473 | ||||||
Other current assets | 1,792 | 1,931 | ||||||
Total current assets | 22,423 | 23,600 | ||||||
Property, plant, and equipment, net | 4,947 | 4,841 | ||||||
Goodwill | 41,224 | 41,500 | ||||||
Other intangible assets, net | 26,209 | 26,899 | ||||||
Tax assets | 1,484 | 1,383 | ||||||
Other assets | 1,291 | 1,421 | ||||||
Total assets | $ | 97,578 | $ | 99,644 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Current debt obligations | $ | 6,226 | $ | 993 | ||||
Accounts payable | 1,557 | 1,709 | ||||||
Accrued compensation | 1,521 | 1,712 | ||||||
Accrued income taxes | 821 | 566 | ||||||
Other accrued expenses | 2,547 | 2,185 | ||||||
Total current liabilities | 12,672 | 7,165 | ||||||
Long-term debt | 25,923 | 30,109 | ||||||
Accrued compensation and retirement benefits | 1,610 | 1,759 | ||||||
Accrued income taxes | 2,527 | 2,903 | ||||||
Deferred tax liabilities | 3,643 | 3,729 | ||||||
Other liabilities | 1,710 | 1,916 | ||||||
Total liabilities | 48,085 | 47,581 | ||||||
Commitments and contingencies | ||||||||
Shareholders’ equity: | ||||||||
Ordinary shares — par value $0.0001 | — | — | ||||||
Retained earnings | 52,266 | 53,931 | ||||||
Accumulated other comprehensive loss | (2,879 | ) | (1,868 | ) | ||||
Total shareholders’ equity | 49,387 | 52,063 | ||||||
Noncontrolling interests | $ | 106 | $ | — | ||||
Total equity | $ | 49,493 | $ | 52,063 | ||||
Total liabilities and equity | $ | 97,578 | $ | 99,644 | ||||
17
MEDTRONIC PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine months ended | ||||||||
(in millions) | January 27, 2017 | January 29, 2016 | ||||||
Operating Activities: | ||||||||
Net income | $ | 2,860 | $ | 2,435 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 2,199 | 2,112 | ||||||
Amortization of debt discount and issuance costs | 21 | 22 | ||||||
Acquisition-related items | (43 | ) | 216 | |||||
Provision for doubtful accounts | 31 | 43 | ||||||
Deferred income taxes | (404 | ) | (291 | ) | ||||
Stock-based compensation | 272 | 291 | ||||||
Other, net | (113 | ) | (117 | ) | ||||
Change in operating assets and liabilities, net of acquisitions: | ||||||||
Accounts receivable, net | 18 | 86 | ||||||
Inventories | (261 | ) | (388 | ) | ||||
Accounts payable and accrued liabilities | (124 | ) | 177 | |||||
Other assets and liabilities | 495 | (399 | ) | |||||
Certain litigation charges | 300 | 26 | ||||||
Certain litigation payments | (144 | ) | (321 | ) | ||||
Net cash provided by operating activities | 5,107 | 3,892 | ||||||
Investing Activities: | ||||||||
Acquisitions, net of cash acquired | (1,328 | ) | (1,132 | ) | ||||
Additions to property, plant, and equipment | (924 | ) | (693 | ) | ||||
Purchases of investments | (3,354 | ) | (4,509 | ) | ||||
Sales and maturities of investments | 4,286 | 4,017 | ||||||
Other investing activities, net | 21 | (11 | ) | |||||
Net cash used in investing activities | (1,299 | ) | (2,328 | ) | ||||
Financing Activities: | ||||||||
Acquisition-related contingent consideration | (58 | ) | (21 | ) | ||||
Change in current debt obligations, net | 1,149 | 1,223 | ||||||
Proceeds from short-term borrowings (maturities greater than 90 days) | 4 | 139 | ||||||
Issuance of long-term debt | 131 | — | ||||||
Payments on long-term debt | (392 | ) | (1,612 | ) | ||||
Dividends to shareholders | (1,782 | ) | (1,608 | ) | ||||
Issuance of ordinary shares | 309 | 360 | ||||||
Repurchase of ordinary shares | (3,409 | ) | (2,170 | ) | ||||
Other financing activities | 80 | 60 | ||||||
Net cash used in financing activities | (3,970 | ) | (3,677 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents | 54 | (9 | ) | |||||
Net change in cash and cash equivalents | (108 | ) | (2,122 | ) | ||||
Cash and cash equivalents at beginning of period | 2,876 | 4,843 | ||||||
Cash and cash equivalents at end of period | $ | 2,768 | $ | 2,721 | ||||
Supplemental Cash Flow Information | ||||||||
Cash paid for: | ||||||||
Income taxes | $ | 474 | $ | 1,236 | ||||
Interest | 626 | 707 | ||||||
18
MEDTRONIC PLC
Q3 FY17
EARNINGS PRESENTATION
FEBRUARY 21, 2017
Exhibit 99.2
• CONSOLIDATED RESULTS & GROUP
REVENUE HIGHLIGHTS
• EPS GUIDANCE, REVENUE OUTLOOK, &
OTHER ASSUMPTIONS
Q3 FY17 Earnings Results | February 21, 2017 | 2
FORWARD LOOKING STATEMENTS
This presentation contains forward-looking statements which provide current expectations or forecasts, including those
relating to market and sales growth, growth strategies, changes to the healthcare system, financial results, use of capital,
balance sheet changes, the creation of shareholder value and shareholder returns, product and service development,
introduction, and adoption, partnerships, regulatory matters, restructuring initiatives, mergers/acquisitions/divestitures and
related effects, accounting estimates, working capital adequacy, currency exchange rates, competitive strengths and sales
efforts. They are based on current assumptions and expectations that involve uncertainties or risks. These uncertainties and
risks include, but are not limited to, those described in the filings we make with the U.S. Securities and Exchange Commission
(SEC). Actual results may differ materially from anticipated results. Forward-looking statements are made as of today's date,
and we undertake no duty to update them or any of the information contained in this presentation.
Financial Data
Certain information in this presentation includes calculations or figures that have been prepared internally and have not been
reviewed or audited by our independent registered public accounting firm. Use of different methods for preparing, calculating
or presenting information may lead to differences and such differences may be material. This presentation contains financial
measures and guidance, including free cash flow figures (defined as operating cash flows less property, plant and equipment
additions), revenue, margin and growth rates on a constant currency basis, and adjusted EPS, all of which are considered “non-
GAAP” financial measures under applicable SEC rules and regulations. We believe these non-GAAP measures provide a useful
way to evaluate our underlying performance. Medtronic calculates forward-looking non-GAAP financial measures based on
internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking
revenue growth and EPS projections exclude the impact of foreign currency exchange fluctuations. Forward-looking non-GAAP
EPS guidance also excludes other potential charges or gains that would be recorded as non-GAAP adjustments to earnings
during the fiscal year, such as amortization of intangible assets and acquisition-related, certain tax and litigation, and
restructuring charges or gains. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS
guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges
or gains is inherently uncertain and difficult to predict, and is unavailable without unreasonable efforts. In addition, we believe
such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have
a substantial impact on GAAP measures of financial performance. Detail concerning how all non-GAAP measures are
calculated, including all GAAP to non-GAAP reconciliations, are provided on our website and can be accessed using this link.
CONSOLIDATED
RESULTS & GROUP
REVENUE HIGHLIGHTS
Q3 FY17 Earnings Results | February 21, 2017 | 4
Balanced growth across groups and geographies
• CVG, MITG, and RTG all MSD growth1; Diabetes HSD growth1
• New products driving growth including Evolut® R 34mm, LigaSure™ instruments,
MiniMed ® 6 series
• Continued improvement in Spine: Best growth in over 7 years
• US MSD growth1; Non-US Developed HSD growth1; Emerging Markets DD growth1
• Western Europe and Japan HSD growth1
• China, Latin America, and Eastern Europe all grew mid-teens or higher1
• Growth Vector Performance:
• New Therapies: above our 200 to 350 bps goal, contributing ~390 bps
• Emerging Markets: in line with our 150 to 200 bps goal, contributing ~150 bps
• Services & Solutions: below our 40 to 60 bps goal, contributing ~20 bps
• MSD Organic Growth2: 4.1%
• Acquisitions & divestitures contributed a net 150 bps to Q3 revenue growth
Meaningful improvement in operating margin; Double-digit EPS1,2 growth
• EPS: 10%1,2 growth; EPS leverage ~480 bps1
• Operating Margin: ~130 bps improvement Y/Y1; ~170bps improvement Y/Y1 on
organic basis2; Operating leverage ~470 bps1
• Covidien synergies: on track for a minimum of $850M in cost savings by FY18
• Delivered $355M in FY16; on track to deliver $225-250M in FY17
Outlook: Continue to expect MSD revenue2 and double-digit EPS2 growth
for the full fiscal year
• Q4 Revenue2: Lower half of MSD range, following strong growth in prior year
• Reiterate FY17 Free Cash Flow3 outlook of $5B - $6B
Capital allocation: Strategically deploying capital against priorities
• Q3: 74% Payout Ratio4; $590M in dividends and $566M in net share repurchases
MDT
Q3 FY17 HIGHLIGHTS
1 Figures represent comparison to Q3 FY16 on a constant currency basis (non-GAAP).
2 Non-GAAP measure
3 Operating cash flows less property, plant and equipment additions (non-GAAP)
4 Dividends plus net share repurchases divided by adjusted net income (non-GAAP)
SOLID QUARTER: IMPROVED RESULTS
ACROSS ALL GROUPS AND GEOGRAPHIES
Revenue:
Other Financial Highlights:
U.S.
56%
Non-
U.S.
Dev
30%
EM
14%
1
Diluted
EPS
Y/Y
CC1
Y/Y%
GAAP $0.59 (23%) NC
Non-GAAP $1.12 6% 10%
Cash Flow
from Ops $2.1B
Free Cash
Flow4 $1.8B
CVG
35%
MITG
33%
RTG
25%
DIAB
7%
Revenue
$M
As Rep
Y/Y %
CC1
Y/Y %
CVG 2,548 5 6
MITG 2,417 5 6
RTG 1,817 4 4
Diabetes 501 6 7
Total $7,283 5% 6%
U.S. 4,106 4 4
Non-U.S. Dev 2,193 6 7
EM 984 9 11
Total $7,283 5% 6%
Q3 FY17 Earnings Results | February 21, 2017 | 5
MDT
Q3 FY17 GAAP SELECT FINANCIAL INFORMATION
Q3
FY17
Q3
FY16
Y/Y Growth /
Y/Y Change
Net Sales ($M) 7,283 6,934 5%
Cost of Products Sold 2,268 2,141 6%
Gross Margin 68.9% 69.1% (20) bps
SG&A ($M) 2,388 2,317 3%
% of Sales 32.8% 33.4% 60 bps
R&D ($M) 530 546 (3%)
% of Sales 7.3% 7.9% 60 bps
Other Expense, Net ($M) 46 9 411%
Operating Profit 1,147 1,355 (15%)
Operating Margin 15.7% 19.5% (380) bps
Diluted EPS ($) 0.59 0.77 (23%)
Q3 FY17 Earnings Results | February 21, 2017 | 6
MDT
Q3 FY17 Y/Y EPS WALK
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
Q3 FY16,
GAAP
Q3 FY16,
Non-GAAP
Adjustments
Q3 FY16,
Non-GAAP
Performance Q3 FY17
CC
FX Q3 FY17,
Non-GAAP
Q3 FY17,
Non-GAAP
Adjustments
Q3 FY17,
GAAP
EPS Growth1: Double-Digit; EPS Leverage1: ~480 bps EPS
$0.77
$0.29 $1.06
1 Figures represent comparison to Q3 FY16 on a constant currency basis (Non-GAAP).
$1.17 ($0.05) $1.12 ($0.53)
$0.59
10% Y/Y1
$0.11
FY16 FY17
Q3 FY17 Earnings Results | February 21, 2017 | 7
MDT
Q3 FY17 Y/Y OPERATING MARGIN CHANGES
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
Q3 FY16,
GAAP
Q3 FY16,
Non-GAAP
Adjustments
Q3 FY16,
Non-GAAP
Performance Q3 FY17
CC
FX Q3 FY17,
Non-GAAP
Q3 FY17,
Non-GAAP
Adjustments
Q3 FY17,
GAAP
~130 bps Operational Improvement1 Operating Margin
19.5%
8.3% 27.8%
1.3% 29.1% (0.9%) 28.2% (12.5%)
15.7%
FY16 FY17
1 Figures represent comparison to Q3 FY16 on a constant currency basis (Non-GAAP).
Q3 FY17 Earnings Results | February 21, 2017 | 8
MDT
Q3 FY17 NON-GAAP SELECT FINANCIAL INFORMATION
Q3
FY17
Q3
FY16
FX
Impact
$M / Change
Q3 FY17
Constant
Currency1
Q3 FY17
CC Growth /
Change2
Net Sales ($M) 7,283 6,934 (40) -- 6%
Cost of Products Sold1 2,268 2,132 10 -- 6%
Gross Margin1 68.9% 69.3% (30) bps 69.2% (10) bps
SG&A ($M) 2,388 2,317 (9) -- 3%
% of Sales 32.8% 33.4% 10 bps 32.7% 70 bps
R&D ($M) 530 546 (1) -- (3%)
% of Sales 7.3% 7.9% Flat 7.3% 60 bps
Other Expense, Net ($M) 46 9 38 -- (11%)
Operating Profit1 2,051 1,930 (78) -- 10%
Operating Margin1 28.2% 27.8% (90) bps 29.1% 130 bps
Diluted EPS1 ($) 1.12 1.06 (0.05) 1.17 10%
1 Non-GAAP
2 Figures represent comparison to Q3 FY16 on a constant currency basis (Non-GAAP).
Operating
Leverage2
+470bps
EPS
Leverage2
+480bps
Q3 FY17 Earnings Results | February 21, 2017 | 9
CVG
Q3 FY17 HIGHLIGHTS
CRHF
54%
CSH
29%
APV
17%
U.S.
52%
Non-
U.S.
Dev
32%
EM
16%
Cardiac Rhythm & Heart Failure (CRHF)
KEY PERFORMANCE DRIVERS1
Heart Failure:+Upper-Teens
• Driven by recent HeartWare
acquisition; integration on track
• CRT-D: MSD growth driven by US
• Japan benefitted from continued
share gains following strong launch
of Compia MRI™ and Amplia MRI ™
• CRT-P: share loss from lack of quad
Arrhythmia Mgmt: +MSD
• WW Tachy: +LSD; strong implants in US
• WW Brady: LSD decline
• US: Modest share decline
• Reveal LINQ® pull-through
• Diagnostics: Mid-teens – Reveal LINQ®
• AF Solutions: Mid-twenties – Continued
share gain in EU/US; Japan >100% growth
Coronary & Structural Heart (CSH)
Aortic & Peripheral Vascular (APV)
Services & Solutions: +LDD
Heart Valve Therapies:
+Upper-Teens
• WW TAVR market growing ~30%
• TAVR : In-line with WW market
•US: seq. share gain on large size Evolut®
R 34mm launch; over 200 accounts
currently
•Share stability in EU
•Japan: Evolut® R launch continues in Q4;
modest share gains seen in early centers
Coronary: -MSD
• DES: LDD decline
• US: mid-20s decline - competitive
product launches
• OUS: LSD decline – Resolute
Onyx™ maintaining share
Aortic: +MSD
• US: Flat growth; Heli-FX® EndoAnchor®:
driving strong growth and AAA pull-
through, offset by competitive headwinds
in TAA
• OUS: HSD growth
• AAA: MSD growth; Endurant® with
ChEVAR indication CE Mark received in Q3
Peripheral & endoVenous:
+HSD
• DCB: US & WW market share leader
• IN.PACT® Admiral® DCB high-30s
• Pricing uplift from 150mm length
• Maintained market leadership in EU
despite pressure on price and
competitive registry enrollment
HSD Growth in CRHF and APV;
LSD growth in CSH
Extracorp. Therapies: -LSD
• Cannulae and Revasc growth offset
by Surgical Ablation decline
Compia
MRI™
SureScan®
CRT-D
CoreValve®
Evolut® R
34mm
Resolute
Onyx™
IN.PACT®
Admiral®
Heli-FX®
EndoAnchor®
Revenue
$M
As Rep
Y/Y %
CC1
Y/Y %
CRHF 1,371 7 8
CSH 751 2 3
APV 426 6 6
Total $2,548 5% 6%
U.S. 1,320 5 5
Non-U.S. Dev 815 5 7
EM 413 7 10
Total $2,548 5% 6%
Arctic Front
Advance®
1 Figures represent comparison to Q3 FY16 on a constant currency basis (Non-GAAP).
Q4 Growth Outlook: MSD
Q3 FY17 Earnings Results | February 21, 2017 | 10
MITG
Q3 FY17 HIGHLIGHTS
Surgical Solutions
KEY PERFORMANCE DRIVERS1
MSD Growth in Surgical Solutions
and PMR
Patient Monitoring & Recovery (PMR)
Early Technologies: +HSD
• Strong growth in GI Solutions
driven by new products including
Barrx™ 360 Express, which helps in
the treatment of Barrett's
Esophagus.
General Surgical: Flat
• Solid growth in OR Safety driven by
our Situate™ technology, a
detection system for retained
surgical sponges, offset due to
softness in Electrosurgery.
Patient Care/ DVT/
Nutritional Insufficiency:
-LSD
• Growth in Nutritional Insufficiency
• DVT: affected by reprocessing in US
Endo GIA™
Bellco
Renal Care Solutions
• Benefitted from Bellco acquisition
• Continued strength from dialyzers
and other consumables revenue
Revenue
$M
As Rep
Y/Y %
CC1
Y/Y %
Surg. Sol. 1,343 6 7
PMR 1,074 5 5
Total $2,417 5% 6%
U.S. 1,234 2 2
Non-U.S. Dev 842 8 8
EM 341 12 14
Total $2,417 5% 6%
ValleyLab™
FT10
PMR
44% Surg.
Sol.
56%
U.S.
51%
Non-
U.S.
Dev
35%
EM
14%
Puritan
Bennett™
980
1 Figures represent comparison to Q3 FY16 on a constant currency basis (Non-GAAP).
LigaSure™
Vessel
Sealing
TRUCLEAR™
Advanced Surgical: +HSD
• Solid growth in Advanced Stapling
driven by innovative new products in
endo stapling specialty reloads.
• Strong growth in Advanced Energy
driven by new LigaSure™ Vessel
Sealing Instruments and ValleyLab™
FT10.
• The business also benefitted from
the Smith & Nephew gynecology
acquisition (TRUCLEAR™).
• US surgical volumes appear stable in
1-2% range.
Respiratory and Monitoring
Solutions: +HSD
• Strong growth in Airways and Ventilation
due to the continued adoption of the
Puritan Bennett™ 980 ventilator.
• Solid growth in our Patient Monitoring
business as a result of strength in
Nellcor™ Pulse Oximetry.
Q4 Growth Outlook: MSD
Q3 FY17 Earnings Results | February 21, 2017 | 11
RTG
Q3 FY17 HIGHLIGHTS
Spine
36%
Brain
29%
Specialty
20%
Pain
15%
US
68%
Non-US
Dev
21%
EM
11%
KEY PERFORMANCE DRIVERS1
Continued Improvement in Spine;
Solid Brain Therapies & Specialty
Therapies Growth Offsets
Declines in Pain Therapies
Neurosurgery: +HSD
• Growth driven by strong performance in
navigation capital (+20%) and disposables
• WW O-arm® O2 driven by robust OUS
demand
Core Spine: +LSD
• US growth driven by new product and
procedural innovation introductions
• Interbody and Discs launches
(Elevate™, OLIF, and Rialto™ for
sacroiliac joint fusion) strong uptake
• Speed-to-scale and surgical synergy
driving implant growth
BMP: +LSD
• US Pricing remains favorable
• InductOs™ return to market expected
mid-FY18
Brain Modulation: +LSD
• US: LSD share loss; competitive
pressure partially mitigated by MRI-
conditional labelling
• EU: revenue growth; competitive
pressure remains
ENT: +LSD
• Continued strong growth in NuVent® driven by
Fusion® Compact penetration
• US growth driven by Power, Balloon & Service
Advanced Energy: +LDD
• Broad geographic expansion led by
China, APAC, and EMEA
• Strong PEAK PlasmaBlade®
disposable growth in Breast,
Generator Replacement markets
InterStim® II
O-arm® O2
Infuse®
Bone Graft
Spine
Brain Therapies
Specialty Therapies
Pain Therapies
Pelvic Health: +MSD
• US growth driven by both new implant and
replacement demand
Neurovascular: +LDD
• Strong sequential and Y/Y growth despite
headwinds from voluntary Q2 recall
Kanghui: +HSD
Revenue
$M
As Rep
Y/Y %
CC1
Y/Y %
Spine 657 3 3
Brain 518 7 8
Specialty 370 4 5
Pain 272 (3) (2)
Total $1,817 4% 4%
U.S. 1,242 3 3
Non-U.S. Dev 384 5 5
EM 191 8 11
Total $1,817 4% 4%
• Growth driven by LatAm, EMEA, APAC
• China growth driven by Spine product
launches (Peek Cage)
SCS/Pumps: -MSD
• US growth in replacement implants, offset
by share loss and new implant declines
• Ongoing SCS competitive pressure
leading to share loss
Interventional: +HSD
• Growth driven by new product
launches including OsteoCool® in EU
• Japan up 25%+ despite competitive
headwinds
OsteoCool®
1 Figures represent comparison to Q3 FY16 on a constant currency basis (Non-GAAP).
Strongest growth in over 7 years; Continue to gain share
Q4 Growth Outlook: Low End of MSD Range
Q3 FY17 Earnings Results | February 21, 2017 | 12
DIABETES
Q3 FY17 HIGHLIGHTS
US
62%
Non-US
Dev
30%
EM
8%
KEY PERFORMANCE DRIVERS1
Intensive Insulin Management (IIM)
Significant Improvement Over
Last Quarter; Strong Interest in
MiniMed® 6 Series Pumps
MiniMed®
630G
Guardian®
Connect
12
Total Group
Revenue
$501M
Revenue
$M
As Rep
Y/Y %
CC1
Y/Y %
IIM ND HSD LDD
NDT ND >15 >15
DSS ND LSD LSD
Total $501 6% 7%
U.S. 310 6 6
Non-U.S. Dev 152 6 9
EM 39 5 5
Total $501 6% 7%
Q4 Growth Outlook: MSD to HSD
MiniMed®
670G
Non-Intensive Diabetes Therapies (NDT)
iPro®2 CGM
w/ Pattern
Snapshot
Diabetes Service & Solutions (DSS)
Improved Patient Retention:
• Substantial sequential improvement in
CGM retention rates
• Patient and physician excitement
driving both installed base growth and
competitive share gains
MiniMed® 640G System:
• Continued strong sales throughout
EMEA and Australia
• Continuing to launch throughout
APAC and Latin America
• Anticipating Japan launch in Q3FY18
MiniMed® 670G System:
• Strong patient participation in the
Priority Access Program; enrollees will
be first in line for 670G
• Early coverage confirmed with many
commercial payers
CGM Adoption:
• iPro® 2 OUS growth from China launch
• Continue to receive positive feedback
for iPro® Pattern Snapshot
i-Port Advance Technology:
• Launches in India, Argentina and Korea
Consumables:
• Solid constant currency growth in
international markets
• LSD declines in U.S. driven by pricing
and challenging prior year comps
Guardian® Connect:
• Positive response to pilot launches in
major European markets
IBM Watson Partnership:
• Preparing for limited preview of
Sugar.IQ™ app; Medtronic Turning
Point platform with IBM now live
Customer Care Programs:
• OUS growth supported by new pro-
active programs to improve adherence
and retention
MiniMed® 630G System:
• Solid US sales, excellent feedback from
patients and providers
• Ongoing physician training
Fitbit Partnership:
• Strategic partnership reached in Q3 to
integrate health and activity tracking for
patients with diabetes
1 Figures represent comparison to Q3 FY16 on a constant currency basis (Non-GAAP).
Diabeter Clinics:
• Strong patient growth
• Global expansion plans moving forward
UNH Partnership:
• Positive coverage decision on 670G
Henry Schein :
• Sales ramped through the quarter;
expect to continue run-rate
FY17 EPS GUIDANCE,
REVENUE OUTLOOK, &
OTHER ASSUMPTIONS
Q3 FY17 Earnings Results | February 21, 2017 | 14
MDT
FY17 EPS GUIDANCE, REVENUE OUTLOOK & OTHER ASSUMPTIONS
Q4 FY17 FY17
Revenue Growth Outlook – CCCW Lower Half of MSD MSD
CVG Growth – CCCW MSD --
MITG Growth – CCCW MSD --
RTG Growth – CCCW Low End of MSD --
Diabetes Growth – CCCW MSD to HSD --
COV Synergies -- ~$225-250M
EPS Growth Guidance– CCCW -- DD
Free Cash Flow1 -- $5B - $6B
Other than noted, revenue and EPS growth guidance do not include any charges or gains that would be recorded as non-GAAP adjustments to earnings during the fiscal year
1 Operating cash flows less property, plant and equipment additions (non-GAAP)
Note: Medtronic will adopt FASB ASU 2016-09 regarding the change in tax treatment of
stock-based compensation in the first quarter of fiscal year 2018.
Outlook & Guidance
FX Assumptions
Q4 FY17 FY17 FY18
Revenue ($20M) – ($40M) ($20M) – ($40M) ($100M) – ($300M)
EPS ~($0.05) ~($0.20) ($0.05) – ($0.15)
Note: While FX rates are fluid, assumptions above are based on current rates.
Q3 FY17 Earnings Results | February 21, 2017 | 15
APPENDIX
ACRONYMS / ABBREVIATIONS
1
Growth
DD Double Digits
HSD High-Single Digit
LDD Low-Double Digits
LSD Low-Single Digit
MSD Mid-Single Digit
Other
APAC Asia Pacific FY Fiscal Year
Bps Basis Points NC Not Comparable
CC Constant Currency Ops Operations
CCCW
Constant Currency
Constant Weeks
OM Operating Margins
Dev Developed OUS
Outside the United
States
EM Emerging Markets R&D
Research &
Development
EMEA
Europe, Middle East &
Africa
Rep Reported
EPS Earnings per Share SG&A
Selling, General &
Administrative
FCF Free Cash Flow WW Worldwide
FX Foreign Exchange Y/Y Year-over-Year
Business Specific
AAA Abdominal Aortic Aneurysm ENT Ear, Nose, & Throat
AF Atrial Fibrillation Extracorp Extracorporeal
APV Aortic & Peripheral Vascular HF Heart Failure
BMP Bone Morphogenetic Protein IIM Intensive Insulin Management
Brady Bradycardia MDT Medtronic
CGM Continuous Glucose Monitoring MITG Minimally Invasive Therapies Group
CRHF Cardiac Rhythm & Heart Failure MRI Magnetic Resonance Imaging
CRT-D
Cardiac Resynchronization Therapy –
Defibrillator
NDT Non-Intensive Diabetes Therapies
CRT-P
Cardiac Resynchronization Therapy –
Pacemakers
NV Neurovascular
CSH Coronary & Structural Heart PMR Patient Monitoring & Recovery
CVG Cardiac & Vascular Group RTG Restorative Therapies Group
DVT Deep Vein Thrombosis SCS Spinal Cord Stimulation
DCB Drug Coated Balloon Sol Solutions
DES Drug Eluting Stent TAVR Transcatheter Aortic Valve Replacement
DSS Diabetes Services & Solutions